Analytical, practical and regulatory issues in prevention studies

Statistics in Medicine

Volumn 23, Issue 2, 2004, Pages 297-303

  Ellenberg, Susan S ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Clinical trials; Disease prevention; Missing data; Safety monitoring; Surrogate endpoints

Indexed keywords

ACETYLSALICYLIC ACID; BACTERIAL VACCINE; BETA CAROTENE; BIOLOGICAL MARKER; CANCER VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; POLIOMYELITIS VACCINE; RETINOL; SMALLPOX VACCINE; VIRUS VACCINE;

ALZHEIMER DISEASE; ARTICLE; BACTERIAL INFECTION; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DIPHTHERIA; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ELDERLY CARE; FREQUENCY ANALYSIS; HEALTH STATUS; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; INFECTION PREVENTION; INFORMATION PROCESSING; MALIGNANT NEOPLASTIC DISEASE; METHODOLOGY; OUTCOMES RESEARCH; PERTUSSIS; POLIOMYELITIS; PREVENTIVE MEDICINE; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; RISK ASSESSMENT; SAFETY; SAMPLE SIZE; SMALLPOX; STATISTICAL ANALYSIS; TETANUS; TREATMENT OUTCOME; UTERINE CERVIX CANCER; VIRUS INFECTION; WART VIRUS;

CLINICAL TRIALS; HUMANS; PATIENT SELECTION; PREVENTIVE MEDICINE; SAFETY; TREATMENT OUTCOME; UNITED STATES;

EID: 0346463159     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.1717     Document Type: Article

References (35)

1. Meinert CL. Clinical Trials. Oxford University Press: New York, 1986; 5.
2. Plotkin SL, Plotkin SA. A short history of vaccination. In Vaccines, Plotkin SA, Orenstein WA (eds). W.B. Saunders Company: Philadelphia, 1999.
3. Meier P. The biggest public health experiment ever: the 1954 field trial of the Salk poliomyelitis vaccine. In Statistics: A Guide to the Unknown, Tanur J, Mosteller F, Kruskal WH, Link RF, Pieters RS, Rising GR, Lehmann EL (eds). Wadsworth & Brooks/Cole: Belmont, CA, 1985.
4. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. Journal of the American Medical Association 1984; 251(3):351-364.
5. Hennekens CH, Buring JE. Methodological considerations in the design and conduct of randomized trials: the U.S. Physicians' Health Study. Controlled Clinical Trials 1989; 10 (Suppl 4):142S-150S.
6. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. New England Journal of Medicine 1994; 330(15):1029-1035.
7. Omenn G, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL, Valanis B, Williams JH, Barnhart S, Hammar S. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. New England Journal of Medicine 1996; 334(18):1150-1155.
8. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Controlled Clinical Trials 1998; 19(1):61-109.
9. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Journal of the American Medical Association 2002; 288(3):321-333.
10. Bell RL, Curb JD, Friedman LM, McIntyre KM, Payton-Ross C. Enhancement of visit adherence in the national beta-blocker heart attack trial. Controlled Clinical Trials 1985; 6(2):89-101.
11. Probstfield JL, Russell ML, Henske JC, Reardon RJ, Insull W Jr. Successful program for recovery of dropouts to a clinical trial. American Journal of Medicine 1986; 80(6):777-784.
12. Probstfield JL. Adherence and its management in clinical trials: implications for arthritis treatment trials. Arthritis Care Research 1989; 2(3):S48-S57.
13. Goldman AI, Holcomb R, Perry HM Jr, Schnaper HW, Fitz AE, Frohlich ED. Can dropout and other noncompliance be minimized in a clinical trial? Report from the Veterans Administration National Heart, Lung and Blood Institute cooperative study on antihypertensive therapy: mild hypertension. Controlled Clinical Trials 1982; 3(2):75-89.
14. Anderson RT, Ory M, Cohen S, McBride JS. Issues of aging and adherence to health interventions. Controlled Clinical Trials 2000; 21(5S):171S-183S.
15. Shumaker SA, Dugan E, Bowen DJ. Enhancing adherence in randomized controlled clinical trials. Controlled Clinical Trials 2000; 21(5S):226S-232S.
16. Yusuf S, Collins R, Peto R. Why do we need some large, simple randomized trials? Statistics in Medicine 1984; 3(4):409-422.
17. Peto R, Collins R, Gray R. Large-scale randomized evidence: large, simple trials and overviews of trials. Journal of Clinical Epidemiology 1995; 48(1):23-40.
18. U.S. Food and Drug Administration. Guidance for Industry: Clinical Considerations for Accelerated and Traditional Approval of Antiretroviral Drugs using Plasma HIV RNA Measurements. www.fda.gov/cder/guidance/3182dft.pdf, 1999.
19. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Statistics in Medicine 1989; 8(4):431-440.
20. Prentice RL. Methodologic challenges in chronic disease population research. Biostatistics 2001; 2(4):365-381.
21. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Annals of Internal Medicine 1996; 125(7):605-613.
22. De Gruttola V, Fleming T, Lin DY, Coombs R. Perspective: validating surrogate markers - are we being naïve? Journal of Infectious Diseases 1997; 175(2):237-246.
23. Temple R. Are surrogate markers adequate to assess cardiovascular disease drugs? Journal of the American Medical Association 1991; 282(8):790-795.
24. Temple R. A regulatory authority's opinion about surrogate endpoints. In Clinical Measurement in Drug Evaluation, Nimmo WS, Tucker GT (eds). Wiley: New York, 1995.
25. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. New England Journal of Medicine 1991; 324(12):781-788.
26. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrott RH. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. American Journal of Epidemiology 1969; 89(4):422-434.
27. Schlecht NF, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura FA, Duarte-Franco E, Rohan TE, Ferenczy A, Villa LL, Franco EL. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. Journal of the American Medical Association 2001; 286(24):3106-3114.
28. See transcript of Advisory Committee meeting at www.fda.gov/ohrms/dockets/ac/01/transcripts/3805t2.doc, 2001.
29. Little RJA, Rubin DB. Statistical Analysis with Missing Data. Wiley: New York, 1987.
30. Carpenter J, Pocock S, Lamm CJ. Coping with missing data in clinical trials: a model based approach applied to asthma trials. Statistics in Medicine 2002; 21(8):1043-1066.
31. Shih WJ, Quan H. Testing for treatment differences with dropouts present in clinical trials - a composite approach. Statistics in Medicine 1997; 16(11):1225-1239.
32. Ellenberg SS, Fleming TR, DeMets DL. Data Monitoring Committees in Clinical Trials: A Practical Perspective. Wiley: Chichester, 2002.
33. Findings from the aspirin component of the ongoing Physicians' Health Study. New England Journal of Medicine 1988; 318(4):262-264.
34. U.S. Food and Drug Administration. Guidance for Clinical Trial Sponsors on the Establishment and Operation of Clinical Trial Data Monitoring Committees. (Draft) www.fda.gov/cber/gdlns/clindatmon.htm, 1999.
35. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N, HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). Journal of the American Medical Association 2002; 288(1):49-57.